Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab.
Boisen MK, Dehlendorff C, Linnemann D, Nielsen BS, Larsen JS, Osterlind K, Nielsen SE, Tarpgaard LS, Qvortrup C, Pfeiffer P, Holländer NH, Keldsen N, Hansen TF, Jensen BB, Høgdall EV, Jensen BV, Johansen JS. Boisen MK, et al. Among authors: nielsen bs, nielsen se. PLoS One. 2014 Oct 15;9(10):e109430. doi: 10.1371/journal.pone.0109430. eCollection 2014. PLoS One. 2014. PMID: 25329796 Free PMC article.
A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer.
Qvortrup C, Jensen BV, Fokstuen T, Nielsen SE, Keldsen N, Glimelius B, Bjerregaard B, Mejer J, Larsen FO, Pfeiffer P. Qvortrup C, et al. Among authors: nielsen se. Ann Oncol. 2010 Jan;21(1):87-91. doi: 10.1093/annonc/mdp272. Epub 2009 Jul 21. Ann Oncol. 2010. PMID: 19622596 Free article. Clinical Trial.
Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.
Boisen MK, Johansen JS, Dehlendorff C, Larsen JS, Østerlind K, Hansen J, Nielsen SE, Pfeiffer P, Tarpgaard LS, Holländer NH, Keldsen N, Hansen TF, Jensen BB, Jensen BV. Boisen MK, et al. Among authors: nielsen se. Ann Oncol. 2013 Oct;24(10):2554-2559. doi: 10.1093/annonc/mdt253. Epub 2013 Jul 17. Ann Oncol. 2013. PMID: 23864097 Free article. Clinical Trial.
Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer.
Chen IM, Johansen AZ, Dehlendorff C, Jensen BV, Bojesen SE, Pfeiffer P, Bjerregaard JK, Nielsen SE, Andersen F, Holländer NH, Yilmaz MK, Rasmussen LS, Johansen JS. Chen IM, et al. Among authors: nielsen se. Cancer Epidemiol Biomarkers Prev. 2020 Jan;29(1):176-184. doi: 10.1158/1055-9965.EPI-19-0672. Epub 2019 Nov 4. Cancer Epidemiol Biomarkers Prev. 2020. PMID: 31685562
Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer.
Schultz NA, Christensen IJ, Werner J, Giese N, Jensen BV, Larsen O, Bjerregaard JK, Pfeiffer P, Calatayud D, Nielsen SE, Yilmaz MK, Holländer NH, Wøjdemann M, Bojesen SE, Nielsen KR, Johansen JS. Schultz NA, et al. Among authors: nielsen kr, nielsen se. PLoS One. 2013 Jun 26;8(6):e67059. doi: 10.1371/journal.pone.0067059. Print 2013. PLoS One. 2013. PMID: 23840582 Free PMC article.
MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
Schultz NA, Dehlendorff C, Jensen BV, Bjerregaard JK, Nielsen KR, Bojesen SE, Calatayud D, Nielsen SE, Yilmaz M, Holländer NH, Andersen KK, Johansen JS. Schultz NA, et al. Among authors: nielsen kr, nielsen se. JAMA. 2014 Jan 22-29;311(4):392-404. doi: 10.1001/jama.2013.284664. JAMA. 2014. PMID: 24449318
The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer.
Johansen JS, Calatayud D, Albieri V, Schultz NA, Dehlendorff C, Werner J, Jensen BV, Pfeiffer P, Bojesen SE, Giese N, Nielsen KR, Nielsen SE, Yilmaz M, Holländer NH, Andersen KK. Johansen JS, et al. Among authors: nielsen kr, nielsen se. Int J Cancer. 2016 Nov 15;139(10):2312-24. doi: 10.1002/ijc.30291. Epub 2016 Aug 16. Int J Cancer. 2016. PMID: 27464352 Free article.
Prognostic impact of Charlson's Age-Comorbidity Index and other risk factors in patients with pancreatic cancer.
Bagni K, Chen IM, Johansen AZ, Dehlendorff C, Jensen BV, Hansen CP, Preus Hasselby J, Holländer NH, Nissen M, Bjerregaard JK, Pfeiffer P, Yilmaz MK, Rasmussen LS, Nielsen SE, Johansen JS. Bagni K, et al. Among authors: nielsen se. Eur J Cancer Care (Engl). 2020 May;29(3):e13219. doi: 10.1111/ecc.13219. Epub 2020 Jan 6. Eur J Cancer Care (Engl). 2020. PMID: 31908093
Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer.
Chen IM, Willumsen N, Dehlendorff C, Johansen AZ, Jensen BV, Hansen CP, Hasselby JP, Bojesen SE, Pfeiffer P, Nielsen SE, Holländer NH, Yilmaz MK, Karsdal M, Johansen JS. Chen IM, et al. Among authors: nielsen se. Int J Cancer. 2020 May 15;146(10):2913-2922. doi: 10.1002/ijc.32751. Epub 2019 Nov 11. Int J Cancer. 2020. PMID: 31642523 Free article.
158 results